Shah Rukh Khan, Ajay Devgn and Tiger Shroff Face FDA Notice Over Vimal Elaichi Ad
BH24 Breaking News
Bollywood stars Shah Rukh Khan, Ajay Devgn and Tiger Shroff have received show-cause notices from the Maharashtra Food and Drug Administration (FDA) over their appearance in a Vimal Elaichi advertisement. The FDA is examining whether the campaign indirectly promotes pan masala through surrogate advertising. The action has brought renewed attention to celebrity endorsements of tobacco-linked brands.
Why Did the FDA Issue Notices?
The FDA has questioned the branding used in the Vimal Elaichi campaign. While elaichi is marketed as a mouth freshener, the Vimal brand is also widely associated with pan masala products. The authority is examining whether the advertisement could indirectly promote the wider pan masala brand. The three actors have been asked to explain their involvement and provide relevant details about the campaign.
Shah Rukh Khan, Ajay Devgn and Tiger Shroff Given 15 Days
The three actors have reportedly been given 15 days to respond to the notices. The FDA has also sought information related to their endorsement agreements and promotional activities. Their responses will help the authority decide whether any further action is required. The notices themselves do not establish that the actors have violated the law.
No Reported Raid on Shah Rukh Khan
Despite claims circulating online, the current action concerns show-cause notices and not a reported raid on Shah Rukh Khan’s residence. The FDA is focusing on the advertisement and its possible connection with surrogate pan masala promotion. The actors will have an opportunity to present their explanations before the authority takes any further decision.
FDA Steps Up Action Against Tobacco Promotion
The Maharashtra FDA has been increasing scrutiny of tobacco-related products and their promotion. The involvement of three major Bollywood stars has made the latest action particularly significant. The FDA will now examine the actors’ responses and the available advertising material before deciding the next course of action. For now, the matter remains under regulatory examination.
